The University of Wisconsin Comprehensive Cancer Center is the first site in the U.S. to install Siemens’ Inveon, a PET, SPECT and CT hybrid-imaging device, which researchers at the university hope will allow them to better visualize and characterize disease.
Inveon’s modular design allows users to image individually or with all three modalities in combination. The system is instrumental for imaging molecular biomarkers enabling the identification of disease pathways, evaluation of disease progress, tracking response to novel therapies and may speed drug development.
“The Inveon establishes and delivers the physical limits of PET and CT imaging, pushing researchers to develop molecular imaging agents that are capable of capitalizing on its incredible resolution and sensitivity. Within hours of receiving the system, we were able to set up and acquire the first preclinical images,” said James Weichert, Ph.D., associate professor of Radiology, University of Wisconsin School of Medicine and Public Health.


Additional Content

News | Molecular Imaging

Editor's Note: This article has been updated to correct an earlier version. Oct. 15, 2026 — GE HealthCare has announced ...

Time October 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 5, 2026 — GE HealthCare has announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based CMO for PET ...

Time October 06, 2026
arrow
News | Radiopharmaceuticals and Tracers

June 1, 2026 — Serac Healthcare Ltd. has presented Phase 2 data showing that SPECT-CT imaging with the radiotracer 99mTc ...

Time June 01, 2026
arrow
News | SNMMI

The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...

Time April 07, 2026
arrow
News | PET Imaging

March 25, 2026 — Catalyst MedTech, a provider of nuclear medicine and molecular imaging solutions, has announced it is ...

Time April 06, 2026
arrow
Subscribe Now